Age Related Macular Degeneration
Conditions
Keywords
macular degeneration, antibodies, angiogenesis inhibitor
Brief summary
The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.
Detailed description
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after photodynamic therapy with verteporfin
Interventions
Sponsors
Asociación para Evitar la Ceguera en México
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR)
Exclusion criteria
* Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual acuity improvement at 6 months | undefined | undefined |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Retinal thickness improvement at 6 months | undefined | undefined |
Countries
Mexico
Outcome results
None listed